Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
Tagawa ST, Ramaswamy K, Huang A, Mardekian J, Schultz NM, Wang L, Sandin R, Lechpammer S, George DJ. Tagawa ST, et al. Among authors: lechpammer s. Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1032-1040. doi: 10.1038/s41391-021-00318-3. Epub 2021 Feb 21. Prostate Cancer Prostatic Dis. 2021. PMID: 33612825 Free PMC article.
Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.
Schultz NM, Flanders SC, Wilson S, Brown BA, Song Y, Yang H, Lechpammer S, Kassabian V. Schultz NM, et al. Among authors: lechpammer s. Adv Ther. 2018 Oct;35(10):1639-1655. doi: 10.1007/s12325-018-0774-1. Epub 2018 Sep 6. Adv Ther. 2018. PMID: 30191463 Free PMC article.
Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
Tagawa ST, Ramaswamy K, Huang A, Mardekian J, Schultz NM, Wang L, Sandin R, Lechpammer S, George DJ. Tagawa ST, et al. Among authors: lechpammer s. Prostate Cancer Prostatic Dis. 2022 Apr;25(4):800-801. doi: 10.1038/s41391-021-00401-9. Prostate Cancer Prostatic Dis. 2022. PMID: 35039606 Free PMC article. No abstract available.
Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
Tagawa ST, Ramaswamy K, Huang A, Mardekian J, Schultz NM, Wang L, Sandin R, Lechpammer S, George DJ. Tagawa ST, et al. Among authors: lechpammer s. Prostate Cancer Prostatic Dis. 2022 Apr;25(4):804. doi: 10.1038/s41391-022-00578-7. Prostate Cancer Prostatic Dis. 2022. PMID: 35840724 Free PMC article. No abstract available.
Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET.
Flanders SC, Kim J, Wilson S, Braziunas J, Greenfield S, Billimek J, Lechpammer S, Lin DW, Karsh L, Quinn DI, Shevrin D, Shore ND, Symanowski JT, Penson DF. Flanders SC, et al. Among authors: lechpammer s. Future Oncol. 2018 Mar;14(6):527-536. doi: 10.2217/fon-2017-0438. Epub 2018 Feb 8. Future Oncol. 2018. PMID: 29417827 Free PMC article.
Cancer consequences of the Chernobyl accident in Europe outside the former USSR: a review.
Sali D, Cardis E, Sztanyik L, Auvinen A, Bairakova A, Dontas N, Grosche B, Kerekes A, Kusic Z, Kusoglu C, Lechpammer S, Lyra M, Michaelis J, Petridou E, Szybinski Z, Tominaga S, Tulbure R, Turnbull A, Valerianova Z. Sali D, et al. Among authors: lechpammer s. Int J Cancer. 1996 Jul 29;67(3):343-52. doi: 10.1002/(SICI)1097-0215(19960729)67:3<343::AID-IJC7>3.0.CO;2-R. Int J Cancer. 1996. PMID: 8707407 Review.
25 results